Cargando…
An unusual case of proton pump inhibitor induced hyperchromograninemia
Objective: To describe an unusual case of symptomatic hyperchromograninemia associated with proton pump inhibitor (PPI) use. Case Summary: A 55-year-old man with stage 1 follicular lymphoma and GERD on omeprazole presented with symptoms suggesting carcinoid syndrome. The only positive finding on wor...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968679/ https://www.ncbi.nlm.nih.gov/pubmed/32002161 http://dx.doi.org/10.1080/20009666.2019.1682748 |
_version_ | 1783489185040039936 |
---|---|
author | Adu-Gyamfi, Kwabena Oware Gyamfi, Richmond Patri, Sandeep |
author_facet | Adu-Gyamfi, Kwabena Oware Gyamfi, Richmond Patri, Sandeep |
author_sort | Adu-Gyamfi, Kwabena Oware |
collection | PubMed |
description | Objective: To describe an unusual case of symptomatic hyperchromograninemia associated with proton pump inhibitor (PPI) use. Case Summary: A 55-year-old man with stage 1 follicular lymphoma and GERD on omeprazole presented with symptoms suggesting carcinoid syndrome. The only positive finding on workup was a markedly elevated level of chromogranin A and no carcinoid tumor was identified. Omeprazole was discontinued, following which his symptoms resolved and chromogranin A levels returned to normal. To the best of our knowledge, no symptoms have been previously reported in association with PPI-induced hyperchromograninemia. Discussion: The reliability of chromogranin A as a marker for neuroendocrine tumors is of growing concern. The reasons for the associated symptomatology in this case are unclear but could involve physiologic effects of chromogranin A breakdown products. The role of pharmacogenomics in PPI metabolism is discussed as a potential explanation for the significant hyperchromograninemia. Conclusion: The phenomenon of PPI-induced hyperchromograninemia is highlighted for providers especially in the context of neuroendocrine tumor diagnosis and surveillance. The need for more research into chromogranins is proposed. |
format | Online Article Text |
id | pubmed-6968679 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-69686792020-01-30 An unusual case of proton pump inhibitor induced hyperchromograninemia Adu-Gyamfi, Kwabena Oware Gyamfi, Richmond Patri, Sandeep J Community Hosp Intern Med Perspect Case Report Objective: To describe an unusual case of symptomatic hyperchromograninemia associated with proton pump inhibitor (PPI) use. Case Summary: A 55-year-old man with stage 1 follicular lymphoma and GERD on omeprazole presented with symptoms suggesting carcinoid syndrome. The only positive finding on workup was a markedly elevated level of chromogranin A and no carcinoid tumor was identified. Omeprazole was discontinued, following which his symptoms resolved and chromogranin A levels returned to normal. To the best of our knowledge, no symptoms have been previously reported in association with PPI-induced hyperchromograninemia. Discussion: The reliability of chromogranin A as a marker for neuroendocrine tumors is of growing concern. The reasons for the associated symptomatology in this case are unclear but could involve physiologic effects of chromogranin A breakdown products. The role of pharmacogenomics in PPI metabolism is discussed as a potential explanation for the significant hyperchromograninemia. Conclusion: The phenomenon of PPI-induced hyperchromograninemia is highlighted for providers especially in the context of neuroendocrine tumor diagnosis and surveillance. The need for more research into chromogranins is proposed. Taylor & Francis 2019-12-14 /pmc/articles/PMC6968679/ /pubmed/32002161 http://dx.doi.org/10.1080/20009666.2019.1682748 Text en © 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of Greater Baltimore Medical Center. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Report Adu-Gyamfi, Kwabena Oware Gyamfi, Richmond Patri, Sandeep An unusual case of proton pump inhibitor induced hyperchromograninemia |
title | An unusual case of proton pump inhibitor induced hyperchromograninemia |
title_full | An unusual case of proton pump inhibitor induced hyperchromograninemia |
title_fullStr | An unusual case of proton pump inhibitor induced hyperchromograninemia |
title_full_unstemmed | An unusual case of proton pump inhibitor induced hyperchromograninemia |
title_short | An unusual case of proton pump inhibitor induced hyperchromograninemia |
title_sort | unusual case of proton pump inhibitor induced hyperchromograninemia |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6968679/ https://www.ncbi.nlm.nih.gov/pubmed/32002161 http://dx.doi.org/10.1080/20009666.2019.1682748 |
work_keys_str_mv | AT adugyamfikwabenaoware anunusualcaseofprotonpumpinhibitorinducedhyperchromograninemia AT gyamfirichmond anunusualcaseofprotonpumpinhibitorinducedhyperchromograninemia AT patrisandeep anunusualcaseofprotonpumpinhibitorinducedhyperchromograninemia AT adugyamfikwabenaoware unusualcaseofprotonpumpinhibitorinducedhyperchromograninemia AT gyamfirichmond unusualcaseofprotonpumpinhibitorinducedhyperchromograninemia AT patrisandeep unusualcaseofprotonpumpinhibitorinducedhyperchromograninemia |